Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024641 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
A Phase 1 study of Hepatitis B Virus Infection, sponsored by GigaGen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 16
- Study locations
NCT07024641: Recruiting Phase 1 study of Hepatitis B Virus Infection, sponsored by GigaGen.
NCT07024641 is a Phase 1 study of Hepatitis B Virus Infection that is actively recruiting participants, run by GigaGen. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07024641, a Phase 1 study of Hepatitis B Virus Infection, is actively recruiting participants, sponsored by GigaGen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 16
- Study locations
Study Summary
The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GIGA-2339
Study Locations (16)
California
- Grifols Investigative site - Huntington Beach
- Grifols Investigative site - Lake Forest
- Grifols Investigative site - Long Beach
- Grifols Investigative site - Oakland
Texas
- Grifols Investigative site - San Antonio
- Grifols Investigative site - Webster
Arizona
- Grifols Investigative site - Chandler
Georgia
- Grifols Investigative Site - Peachtree Corners
Iowa
- Grifols Investigative Site - Iowa City
Kansas
- Grifols Investigative Site - Lenexa
Maryland
- Grifols Investigative site - Baltimore
Virginia
- Grifols Investigative site - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-11-13 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
What NCT07024641 shows while recruiting
NCT07024641 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Hepatitis B Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07024641 lists 16 locations in 12 states (California, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT07024641 about?
NCT07024641 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection". The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
What is the current status of trial NCT07024641?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2024-11-13. Estimated completion is 2027-09.
What conditions does trial NCT07024641 study?
This clinical trial studies the following conditions: Hepatitis B Virus Infection.
What interventions are being tested in trial NCT07024641?
The interventions under investigation include: Placebo (DRUG), GIGA-2339 (DRUG).
Who is sponsoring clinical trial NCT07024641?
This trial is sponsored by GigaGen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024641 being conducted?
This trial has 16 study locations across Arizona, California, Georgia, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07024641's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI